The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices

References

• Neumann PJ, Kim DD, Trikalinos TA, et al. Future directions for cost-effectiveness analyses in health and medicine. Med Decis Making. 2018 Oct;38(7):767–777.
   PubMed Web of Science ®Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th. Oxford (OX): Oxford university press; 2015.
   Google Scholar
• Rothery C, Strong M, Koffijberg HE, et al. Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020 Mar;23(3):277–286.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford (OX): Oup Oxford; 2006.
   Google Scholar
• Wilson ECF. A Practical Guide to Value of Information Analysis. PharmacoEconomics. 2015 [2015 Feb 01];33(2):105–121.
   PubMed Web of Science ®Google Scholar
• Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford (OX): Oxford University Press; 2001. p. 172–214.
   Google Scholar
• CADTH. 2017. Guidelines for the economic evaluation of health technologies: Canada. 4th ed., Ottawa, Canada.
   Google Scholar
• NICE. Guide to the methods of technology appraisal 2013. 2013.
   Google Scholar
• AMCP. The AMCP Format for Formulary Submissions. 4th ed. Alexandria VA: Academy of Managed Care Pharmacy; 2016.
   Google Scholar
• EUnetHTA. Methods for health economic evaluations – a guideline based on current practices in Europe. 2015.
   Google Scholar
• Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2(2):147–157.
   Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998;18(2_suppl):S68–S80.
   PubMed Web of Science ®Google Scholar
• Monnickendam G, Zhu M, McKendrick J, et al. Measuring survival benefit in health technology assessment in the presence of nonproportional hazards. Value Health. 2019;22(4):431–438.
   PubMed Web of Science ®Google Scholar
• Yuan F, Bangdiwala SI, Tong W, et al. Projecting effectiveness after ending a randomized controlled trial: a two-state Markov microsimulation model. Int J Technol Assess Health Care. 2020;3:1–8.
   Google Scholar
• Lueza B, Mauguen A, Pignon J-P, et al. Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: evidence from a case study. PLoS One. 2016;11(3):e0150032.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 2016.
   Google Scholar
• Cochran WG. Sampling Techniques. New York: John Wiley & Sons; 1977.
   Google Scholar
• Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol. 2017;33(8):1027–1035.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
   PubMed Web of Science ®Google Scholar
• Rice JA. Mathematical statistics and data analysis. 2 ed. California (CA): Duxbury Press; 1995.
   Google Scholar
• Fernandes M. Statistics for business and economics. Marcelo Fernandes & Ventus Publishing ApS; 2009.
   Google Scholar
• Lamy A, Tong W, Gao P, et al. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2012 Jan-Feb;28(1):95–101.
   PubMed Web of Science ®Google Scholar
• Lamy A, Tong W, Jung H, et al. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complications. 2014 Jul-Aug;28(4):553–558.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American college of cardiology/American heart association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol. [2014 Jun 3];63(21):2304–2322.
   PubMed Web of Science ®Google Scholar
• Paulden M. Calculating and interpreting icers and net benefit. Pharmacoeconomics. 2020 Aug;38(8):785–807.
   PubMed Web of Science ®Google Scholar
• Paulden M. Why it’s time to abandon the ICER. Pharmacoeconomics. 2020 Aug;38(8):781–784.
   PubMed Web of Science ®Google Scholar
• Willan AR, O’Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller’s theorem. Health Econ. 1996 Jul-Aug;5(4):297–305.
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Johannesson M, Jönsson B, et al. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics. 2003;21(1):39–48.
   PubMed Web of Science ®Google Scholar
• Eckermann S. Health economics from theory to practice - optimally informing joint decisions of research, reimbursement and regulation with health system budget constraints and community objectives. Springer International Publishing AG; 2017.
   Google Scholar
• O’Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994 Feb;32(2):150–163.
   PubMed Web of Science ®Google Scholar
• Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996 Jul 15;15(13):1447–1458.
   PubMed Web of Science ®Google Scholar
• Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 1997 May-Jun;6(3):243–252.
   PubMed Web of Science ®Google Scholar
• Vogler S. Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):321–325.
   PubMed Web of Science ®Google Scholar
• Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Cmaj. 2002 Jan 8;166(1):44–47.
   PubMed Web of Science ®Google Scholar
• Mardetko N, Kos M, Vogler S. Review of studies reporting actual prices for medicines. Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):159–179.
   PubMed Web of Science ®Google Scholar
• Persson U, Jönsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016 Feb;14(1):1–8.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1–134.
   PubMedGoogle Scholar
• Casella G, Berger RL. Statistical Inference. Duxbury/Thomson Learning. 2002:47–82.
   Google Scholar
• Soares MO, Canto ECL. Continuous time simulation and discretized models for cost-effectiveness analysis. Pharmacoeconomics. 2012 Dec 1;30(12):1101–1117.
   PubMed Web of Science ®Google Scholar
• Foong NS, Chin LH, Hoe QS. An overview of biased estimators. J Phys Sci. 2007;18:89–106.
   Google Scholar
• Mandal PP, Rezaee R, Emelyanova I. Ensemble learning for predicting TOC from well-logs of the unconventional goldwyer shale. Energies. 2021;15(1):216.
   Web of Science ®Google Scholar
• Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990 Jul-Sep;10(3):212–214.
   PubMed Web of Science ®Google Scholar